Publikationsserver
Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection
Background: Lassa virus (LASV) can cause severe acute systemic infection in humans. No approved antiviral drugs or vaccines are currently available. Antibody-based therapeutics are considered a promising treatment strategy in the management of LASV disease. Methods: We used chimeric Ifnar?/? C57B...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Статья |
| Язык: | английский |
| Опубликовано: |
Philipps-Universität Marburg
2023
|
| Предметы: | |
| Online-ссылка: | PDF-полный текст |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
| Итог: | Background: Lassa virus (LASV) can cause severe acute systemic infection in humans.
No approved antiviral drugs or vaccines are currently available. Antibody-based therapeutics are
considered a promising treatment strategy in the management of LASV disease. Methods: We
used chimeric Ifnar?/? C57BL/6 (Ifnar?/? Bl6) mice, a lethal LASV mouse model, to evaluate the
protective efficacy of polyclonal antibodies purified from sera of rabbits hyperimmunized with viruslike
particles displaying native-like LASV glycoprotein GP spikes. Results: Polyclonal anti-LASV
GP antibodies provided 100% protection against lethal LASV infection in a pre- and post-exposure
treatment setting and prevented LASV disease. Treatment also significantly lowered viremia level
and virus load in organs. When treatment was initiated at the onset of symptoms, the hyperimmune
antibodies provided partial protection and increased the survival rate by 80%. Conclusions: Our
findings support the consideration of animal-derived hyperimmune antibodies targeting GP as an
effective treatment option for highly pathogenic LASV. |
|---|---|
| Примечание: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
| DOI: | 10.3390/v15071436 |